Janux Therapeutics, Inc.

NASDAQ (USD): Janux Therapeutics, Inc. (JANX)

Last Price

23.44

Today's Change

+0.565 (2.46%)

Day's Change

22.83 - 24.18

Trading Volume

231,536

Overview

Market Cap

1 Billion

Shares Outstanding

59 Million

Avg Volume

968,677

Avg Price (50 Days)

26.62

Avg Price (200 Days)

40.16

PE Ratio

-17.17

EPS

-1.36

Earnings Announcement

05-Aug-2025

Previous Close

22.88

Open

23.35

Day's Range

22.89 - 23.74

Year Range

22.48 - 71.71

Trading Volume

456,336

Price Change Highlight

1 Day Change

2.08%

5 Day Change

2.05%

1 Month Change

-7.41%

3 Month Change

-24.26%

6 Month Change

-57.68%

Ytd Change

-56.14%

1 Year Change

-43.69%

3 Year Change

85.32%

5 Year Change

-7.16%

10 Year Change

-7.16%

Max Change

-7.16%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment